David P Humphreys
Overview
Explore the profile of David P Humphreys including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
630
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Peters S, Smales C, Henry A, Stephens P, West S, Humphreys D
J Biol Chem
. 2012 May;
287(29):24525-33.
PMID: 22610095
The integrity of antibody structure, stability, and biophysical characterization are becoming increasingly important as antibodies receive increasing scrutiny from regulatory authorities. We altered the disulfide bond arrangement of an IgG4...
22.
Weatherill E, Cain K, Heywood S, Compson J, Heads J, Adams R, et al.
Protein Eng Des Sel
. 2012 May;
25(7):321-9.
PMID: 22586154
Engineered introduction of interface interchain disulphide bonds is perceived to be a simple method to increase the stability of single chain Fv (scFv). Six disulphide bond locations have been cited...
23.
Blower T, Pei X, Short F, Fineran P, Humphreys D, Luisi B, et al.
Nat Struct Mol Biol
. 2011 Jan;
18(2):185-90.
PMID: 21240270
The ≥ 10³⁰ bacteriophages on Earth relentlessly drive adaptive coevolution, forcing the generation of protective mechanisms in their bacterial hosts. One such bacterial phage-resistance system, ToxIN, consists of a protein...
24.
Fineran P, Blower T, Foulds I, Humphreys D, Lilley K, Salmond G
Proc Natl Acad Sci U S A
. 2009 Jan;
106(3):894-9.
PMID: 19124776
Various mechanisms exist that enable bacteria to resist bacteriophage infection. Resistance strategies include the abortive infection (Abi) systems, which promote cell death and limit phage replication within a bacterial population....
25.
Humphreys D, Heywood S, Henry A, Ait-Lhadj L, Antoniw P, Palframan R, et al.
Protein Eng Des Sel
. 2007 Apr;
20(5):227-34.
PMID: 17452434
Antigen-binding fragments (Fab') of antibodies can be site specifically PEGylated at thiols using cysteine reactive PEG-maleimide conjugates. For therapeutic Fab'-PEG, conjugation with 40 kDa of PEG at a single hinge...
26.
Humphreys D, Heywood S, King L, Bowering L, Turner J, Lane S
Protein Expr Purif
. 2004 Aug;
37(1):109-18.
PMID: 15294288
Escherichia coli is a widely used host for the heterologous expression of proteins of therapeutic and commercial interest. The scale and speed at which it can be cultured can result...
27.
Humphreys D
Curr Opin Drug Discov Devel
. 2003 Apr;
6(2):188-96.
PMID: 12669454
Antibody-based drugs are now used in the clinic, and their importance as therapeutics is expected to increase in the coming decade, both in terms of diseases treated and market value....
28.
Humphreys D, Carrington B, Bowering L, Ganesh R, Sehdev M, Smith B, et al.
Protein Expr Purif
. 2002 Oct;
26(2):309-20.
PMID: 12406686
We demonstrate the importance of optimizing the balance of light chain (LC) and heavy chain (HC) expression to achieve high level production of Fab' fragments in the Escherichia coli periplasm....